Glucocorticoid-induced osteoporosis: pathogenesis and prevention

Osteoporosis (OP) along with myocardial infarction, oncological diseases and expected death takes the lead in the general morbidity and mortality profile of population. The indicators of primary and general incidence of OP are markedly different in the regions of Russia according to the Healthcare Monitoring, Analysis and Strategic Development Department of the Central Research Institute of Organization and Informatization of Healthcare of the Ministry of Health of Russia and according to the data of epidemiological studies. Osteoporosis is classified as primary, if it develops in postmenopausal women or in older men in the absence of any underlying predisposing disease, and as secondary if there is a pathogenetic relationship with the disease or drug intake. The glucocorticoidinduced osteoporosis, which is distinguished in the International Classification System of Diseases and Death Causes (X revision) under code M 81.4 - drug-induced osteoporosis is the most common form of secondary osteoporosis. The topic of glucocorticoidinduced OP affects the professional fields of a significant number of medical specialties in connection with the common use of glucocorticosteroids in medicine. This article presents the issues of epidemiology, pathogenesis, complications of glucocorticoid-induced OP. Particular attention is paid to the prevention of this disease, including such non-pharmacological methods as a balanced diet, body weight gain to the recommended values, smoking cessation, regular exercise against weightlifting and resistance, protection against falls. Drug prophylaxis of glucocorticoid-induced OP is focused on the rational treatment to target of the underlying disease and the use of complex drugs containing vitamin D, calcium and synergistic osteotropic micronutrients.

1. Dedov I.I., Melnichenko G.A. Osteoporosis. Clinical guidelines. М.: Ministry of Health of the RF; 2016. 104 p. (In Russ.) Available at: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/rec_osteoporosis_2016.pdf.

2. Cannarella R., Barbagallo F., Condorelli R.A., Aversa A., La Vignera S., Calogero A.E. Osteoporosis from an Endocrine Perspective: The Role of Hormonal Changes in the Elderly. J Clin Med. 2019;8(10):1564. doi: 10.3390/jcm8101564.

3. Toroptsova N.V., Nikitinskaya O.A., Benevolenskaya L.I. Primary osteoporosis prophylaxis with different calcium preparations. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2005;43(1):36-39. (In Russ.) doi: 10.14412/1995-4484-2005-554.

4. Verbovoy A.F., Pashentseva A.V., Sharonova L.A. Osteoporosis: Current state of the art. Terapevticheskij arxiv = Therapeutic arkhive. 2017;89(5):90-97. doi: 10.17116/terarkh201789590-97.

5. Liu J., Curtis E.M., Cooper C. et al. State of the art in osteoporosis risk assessment and treatment. J Endocrinol Invest. 2019;(42):1149–1164. doi: 10.1007/s40618-019-01041-6.

6. Kanis J.A., Odén A., McCloskey E.V. et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos. 2012;(23):2239–2256. doi: 10.1007/s00198-012-1964-3.

7. Lesnyak O.M. Osteoporosis: audit of problem in Russian Federation. Profilakticheskaya meditsina = Preventive Medicine. 2011;14(2):7-10. (In Russ.) Available at: https://www.mediasphera.ru/issues/terapevticheskijarkhiv/2017/5/downloads/ru/1004036602017051090.

8. Mirza F., Canalis E. Secondary osteoporosis: pathophysiology and management Eur J Endocrinol. 2015;173(3):R131–R151. doi: 10.1530/EJE-15-0118.

9. Doskina E.V. Osteoporosis patient at a GP appointment: where to start and what to look for? Terapiya = Therapy. 2017;5(15):22–28. (In Russ.) Available at: https://therapy-journal.ru/ru/archive/edition/9815.

10. Haugeberg G., Orstavik R.E., Uhlig T., et al. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. Arthritis Rheum. 2002;46(7):1720–1728. doi: 10.1002/art.10408.

11. Kvien T.K., Haugeberg G., Uhlig T., et al. Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis. Ann Rheum Dis. 2000;(59):805–11. doi: 10.1136/ard.59.10.805.

12. Lodder M.C., Haugeberg G., Lems W.F., et al. Radiographic Damage Associated With Low Bone Mineral Density and Vertebral Deformities in Rheumatoid Arthritis: The Oslo-Truro-Amsterdam (OSTRA) Collaborative Study. Arthritis Rheum. 2003;49(2):209–15. doi: 10.1002/art.10996.

13. Oelzner P., Schwabe A., Lehmann G., et al. Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int. 2008;28(11):1143–50. doi: 10.1007/s00296-008-0576-x.

14. Taskina E.A., Alekseeva L.I. Risk factors for osteoporosis in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):562–571. doi: 10.14412/1995-4484-2014-562-571.

15. Cushing’s basophilism: clinical guidelines. 2016. (In Russ.) Available at: https://rae-org.ru/system/files/documents/pdf/kr84_bolezn_icenkokushinga.pdf.

16. Belaya Z.E., Rozhinskaya L.Y., Solodovnikov A.G., Dragunova N.V., Melnichenko G.A. Glucocorticoid-induced osteoporosis: fractures and bone remodeling in patients with endogenous Cushing’s syndrome. Series: Endocrinology Research and Clinical Developments. Online Book, Published by Nova Science Publishers, Inc New-York; 2013. 55 p.

17. Tsoriev T.T., Belaya Zh.E., Rozhinskaya L.Y., Nikankina L.V. Evalution of diagnostic potential of the collagen osteogenesis marker (P1NP) compared with osteocalcin in Cushing’s disease. Osteoporosis and Bone Diseases = Osteoporoz i osteopatii. 2019;22(1):10-17. (In Russ.) doi: 10.14341/osteo10266.

18. Tsoriev T.T., Belaya Zh.E., Rozhinskaya L.Y., Mel’nichenko G.A., Ilyin A.V., Nikankina L.V., Dedov I.I. New biomarkers of bone remodeling regulation in patients with acromegaly and endogenous hypercortisolism. Obesity and metabolism = Ozhirenie i metabolism. 2018;15(3):33-41. doi: 10.14341/omet9447.

19. van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;(13):777–787. doi: 10.1007/s001980200108.

20. van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000. doi: 10.1359/jbmr.2000.15.6.993.

21. Van Staa Т.Р., Leufkens H .G.M., Abenhaim L. et al. Use of oral corticosteroids in the United Kingdom. Q J Med. 2000;93(2):105-111. doi: 10.1093/qjmed/93.2.105.

22. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;(22):809–816. doi: 10.1007/s00198-010-1524-7.

23. Dydykina I.S., Baranova I.A., Maslova K.A., Benevolenskaya L.I. Glucocorticoid-induced osteoporosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2005;43(1):69-75. (In Russ.) doi: 10.14412/1995-4484-2005-561.

24. Folomeeva O.M., Nasonov E.L., Andrianova I.A., et al. Rheumatoid arthritis in rheumatological care of Russia: The severity of the disease in a russian patient population: A cross-sectional epidemiological study (RAISER). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2010;48(1):50-60. (In Russ.) doi: 10.14412/1995-4484-2010-1406.

25. Nikitinskaya O.A., Toroptsova N.V., Demin N.V., Feklistov A.Y., Nasonov E.L. The risk of osteoporotic fractures in patients with rheumatoid arthritis: results of the program «Osteoscreening Russia». Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):310-315. (In Russ.) doi: 10.14412/1995-4484-2018-310-315.

26. Barbour K.E., Lui L.Y., Ensrud K.E., Hillier T.A., LeBlanc E.S., Ing S.W. et al. Inflammatory markers and risk of hip fracture in older white women: the study of osteoporotic fractures. J Bone Miner Res. 2014;29(9):2057-2064. doi: 10.1002/jbmr.2245.

27. van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2000;13(10):777-787. doi: 10.1007/s001980200108.

28. De Vries F., Bracke M., Leufkens H.G., Lammers J.W., Cooper C., Van Staa T.P. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56(1):208–214. doi: 10.1002/art.22294.

29. Israel E., Banerjee T.R., Fitzmaurice G.M., Kotlov T.V., LaHive K., LeBoff M.S. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;(345):941–947. doi: 10.1056/NEJMoa002304.

30. Canalis E., Mazziotti G., Giustina A., Bilezikian J.P. Glucorticoid-Induced Osteoporosis: Pathophysiology and Therapy. Osteoporos Int. 2007;(18):1319–1328. doi: 10.1007/s00198-007-0394-0.

31. Pereira R.C., Delany A.M., Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone. 2002;30(5):685–691. doi: 10.1016/s8756-3282(02)00687-7.

32. Delany A.M., Durant D., Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol. 2001;15(10):1781–1789. doi: 10.1210/mend.15.10.0704.

33. Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535–559. doi: 10.1210/er.2007-0036.

34. Dallas S.L., Prideaux M., Bonewald L.F. The osteocyte: an endocrine cell ... and more. Endocr Rev. 2013;34(5):658–690. doi: 10.1210/er.2012-1026.

35. Hartmann K., Koenen M., Schauer S. et al. Molecular Actions of Glucocorticoids in Cartilage and Bone During Health, Disease, and Steroid Therapy. Physiol Rev. 2016;96(2):409-447. doi: 10.1152/physrev.

36. 2015

37. Yakar S., Canalis E., Sun H., Mejia W., Kawashima Y., Nasser P., et al. Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions. J Bone Miner Res. 2009;24(8):1481-1492. doi: 10.1359/jbmr.090226.

38. Baranova I.A., Rrshova O.B., Anaev E.Kh. Analysis of the state-of-the-art of consulting medical care to patients with glucocorticoidinduced osteoporosis or its risk according to the data of a questionnaire survey (GLUCOST study). Terapevticheskij arxiv = Therapeutic arkhive. 2015;87(5):58-64. (In Russ.) doi: 10.17116/terarkh201587558-64.

39. Ershova O.B., Belova K.Yu., Barysheva Yu.V., et al. The mutifactorial pattern of osteoporosis: A review of the researches of the Department of Therapy, Institute of Postgraduate Education, Yaroslavl State Medical University. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(2):187-190. (In Russ.) doi: 10.14412/1995-4484-2016-187-190.

40. Laan R.F., van Riel P.L., van de Putte L.B., et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann Intern Med. 1993;119(10):963-968. doi: 10.7326/0003-4819-119-10-199311150-00001.

41. Hall G.M., Spector T.D., Griffin A.J., et al. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum. 1993;36(11):1510-1516. doi: 10.1002/art.1780361105.

42. Toroptsova N.V. Review of American College of Rheumatology (ACR) clinical guidelines for the prevention and treatment of glucocorticoidinduced osteoporosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(2):144-151. (In Russ.) doi: 10.14412/1995-4484-2018-144-151.

43. Dydykina I.S., Alekseeva L.I. Osteoporos pri reumatoidnom artrite: diagnostika, factory riska, perelomy, lechenie. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(5):13-17. (In Russ.) doi: 10.14412/1995-4484-2011-1454.

44. Buckley L.M., Leib E.S., Cartularo K.S., Vacek P.M., Cooper S.M. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double- blind, placebo-controlled trial. Ann Intern Med. 1996;(125):961–968. doi: 10.7326/0003-4819-125-12-199612150-00004.

45. Raterman H.G., Bultink I.E.M., Lems W.F. Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis. Drugs. 2019 Jul;79(10):1065-1087. doi: 10.1007/s40265-019-01145-6.

46. Rossini M., Viapiana O., Vitiello M. et al. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo. 2017;69(1):30-39. doi: 10.4081/reumatismo.2017.922.

47. Park S.Y., Gong H.S., Kim K.M. et al. Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. J Bone Metab. 2018;25(4):195-211. doi: 10.11005/jbm.2018.25.4.195.

48. Buckley L., Guyatt G., Fink H.A., et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2017;69(8):1521-1537. doi: 10.1002/art.40137.

49. Evstigneeva L.P., Kozhemyakina E.V., Negodaeva E.V. et al. Efficacy of psysical exercises in patients with osteoporotic vertebral fractures. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):49-55. (In Russ.) doi: 10.14412/1995-4484-2014-49-55.

50. Evstigneeva L.P., Lesnyak O.M., Kuznetsova N.M. et al. Educating patients with osteoporosis: results of a multicenter randomized study. Profilakticheskaya meditsina = Preventive Medicine. 2013;16(1):18-24. (In Russ.) Available at: https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2013/1/031726 6130201314.

51. Pereira R.M., Carvalho J.F., Paula A.P. et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol. 2012;52(4):580–593. Available at: https://medblog.su/prochietematiki/osobennosti-pobochnyh-effektovglyukokortikoidov-v-sravnenii-s-proyavleniyami-endogennogo-giperkortitsizma-drevala-v-budul-n-a-komerdus-i-v-britvin-t-aglazkov-a-a.html.

52. Gavisova A.A., Tverdikova M.A., Jakuchevskaja O.B.. Osteoporosis: a modern view of the problem. RMZh = RMJ. 2012;(21):1110–1113. (In Russ.) Available at: https://lechenie-osteoporoza.ru/osteoporoz-sovremennyy-vzglyadna-problemu-2/.

53. Toroptsova N.V., Feklistov A.Y. The risk of falls in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):705-711. (In Russ.) doi: 10.14412/1995-4484-2016-705-711.

54. Choi H.K. Dietary risk factors for rheumatic diseases. Curr Opin Rheumatol. 2005;17(2):141–6. doi: 10.1097/01.cco.0000152664.87204.3c.

55. Benito-Garcia E., Feskanich D., Hu F.B., et al. Protein, iron, and meat consumption and risk for rheumatoid art ± hritis: a prospective cohort study. Arthritis Res Ther. 2007;9(1):R16. doi: 10.1186/ar2123.

56. Martinchik A.N., Baturin A.K., Martinchik E.A., et al. Actual consumption of antioxidant vitamins population of Russia. Voprosy` pitaniya = Voprosy pitaniya. 2005;74(4):9–13 (In Russ.) Available at: https://cyberleninka.ru/article/n/15663413.

57. Khodyrev V.N., Martinchik A.N., Lesnyak O.M., et al. Provision of vitamins and calcium in rheumatoid arthritis: Estimation of intake and plasma concentrations. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):38–44. doi: 10.14412/1995-4484-2015-38-44.

58. Nikitinskaya O.A., Toroptsova N.V. The social program «Osteoskrining Russia» in action. Farmateka = Farmateka. 2012;(6):90–3 (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/8412.

59. Bolland M.J., Grey A., Avenell A. et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;(342):d2040. doi: 10.1136/bmj.d2040.

60. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the Tolerable Upper Intake Level of calcium. EFSA Panel on Dietetic Products, Nutrition and Allergies. EFSA Journal. 2012;10(7):2814–2857. Available at: http://journaldatabase.info/articles/scientific_opinion_on_tolerable_upper_intake.html.

61. Lesnyak O.M., Nikitinskaya O.A., Toroptsova N.V., et al. The prevention, diagnosis, and treatment of vitamin D and calcium deficiencies in the adult population of Russia and in patients with osteoporosis (according to the materials of prepared clinical recommendation). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):403–408. (In Russ.) doi: 10.14412/1995-4484-2015-403-408.

62. Lips P. Vitamin D deficiency and osteoporosis: the role of vitamin D deficiency and treatm ent with vitamin D and analogues in the prevention of osteoporosis related fractures. Eur J Clin. Invest. 1996;26(6):436-442. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8817154.

63. Gromova O.A., Torshin I.YU., Limanova O.A. Calcium and its synergists in support of connective and bone tissue structure. Lechashchiy vrach. 2014;(5):69-74. (In Russ.) Available at: https://www.lvrach.ru/2014/05/15435966/.

64. Nikitinskaya O.A., Toroptsova N.V., Nasonov E.L. Osteoporosis treatment adherence: results from a retrospective cohort study. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(4):415-420. (In Russ.) doi: 10.14412/1995-4484-2019-415-420.